Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Watchlist flags troubled small-cap stocks with slowing sales, margin compression, cash burn and elevated leverage, while highlighting cash-generating and potential rebound candidates.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Watchlist flags troubled small-cap stocks with slowing sales, margin compression, cash burn and elevated leverage, while highlighting cash-generating and potential rebound candidates.